We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look ...

The stent hadn’t helped after all; the impacted kidney had, in fact, been irreversibly damaged and was now functioning at a ...

We recently published a list of the 15 Best and Cheap Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands ...

CAR-T pipeline advances, with blood cancers at the forefront of development, driving new treatment innovations.

Among the 13 CAR-T therapeutics that have received regulatory approval are Gilead’s Yescarta and Immuneel Therapeutics’ ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Breyanzi’s approval is based on the TRANSCEND NHL 001 trial involving 268 patients, which showed that 54% of those taking Breyanzi had minimal or no detectable lymphoma remaining after treatment ...

A third CD19-targeted CAR-T, Bristol-Myers Squibb's Breyanzi (lisocabtagene maraleucel), is on the market for other blood cancers, but not ALL. Aucatzyl will now have to carve out market share ...

Final guidance published today recommends lisocabtagene maraleucel (also known as liso-cel or Breyanzi, made by Bristol Myers ...